Independent
Tenure on this board
12.4 yrs
Also a director at
Veracyte Inc (VCYT)
Meeting calendar
FATE · Annual meeting · Friday, June 12, 2026
Fate Therapeutics Inc
3 nominees · 4 ballot items.
Election of three Class I directors; Ratification of Ernst & Young LLP as independent auditors; Non-binding advisory approval of named executive officer compensation; Approval to amend and restate 2022 Stock Option and Incentive Plan to increase share reserve by 7,000,000 shares.
Market cap
$324M
1Y TSR
+123.2%
Board grade
C-
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 12, 2026
Follow how the vote landed and what changed on Fate Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Directors
ManagementBoard: FORElection of three Class I directors (Robert S. Epstein, Karin Jooss, and Laura J. Hamill) to serve until the 2029 Annual Meeting.
- 2
Ratification of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2026.
- 3
Non-Binding Advisory Vote to Approve Named Executive Officer Compensation
ManagementBoard: FORConduct a non-binding advisory (say-on-pay) vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.
- 4
Approval of Third Amendment and Restatement of 2022 Stock Option and Incentive Plan
ManagementBoard: FORApprove the third amendment and restatement of the 2022 Plan to increase the number of shares reserved for issuance under the plan by 7,000,000 shares (from 24,500,000 to 31,500,000).
More detail
The Board proposes an amendment and restatement of the 2022 Stock Option and Incentive Plan to add 7,000,000 shares to the plan reserve, increasing it to 31,500,000 shares. Management seeks approval to ensure sufficient shares for equity awards to attract, retain, and motivate employees, directors and consultants given competitive labor markets and the Company’s hiring and retention needs. The filing explains the Company’s historical and projected burn rates, the overhang relative to peers, and Aon’s analysis supporting the requested increase. The proposal would not add an evergreen feature and contains governance protections including no single-trigger acceleration on a sale event unless awards are not assumed, no repricing without stockholder approval, and director compensation limits. Failure to approve would leave the Company with its existing share reserve and could limit its ability to grant equity awards, potentially prompting increased cash compensation or alternative arrangements. The Board recommends a shareholder vote FOR this proposal as necessary to preserve the Company’s ability to implement its compensation strategy and maintain competitive positioning.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
7.3 yrs
Independent
Tenure on this board
0.1 yrs
Also a director at
Jazz Pharmaceuticals PLC (JAZZ)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Redmile Group, LLC | 11.0% | 12,872,946 | $15M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 4,192,063 | $5M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 4,134,585 | $5M |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 3.5% | 4,120,200 | $5M |
| 5 | BlackRock, Inc. | 3.5% | 4,048,767 | $5M |
| 6 | BlackRock, Inc. | 3.4% | 3,915,865 | $5M |
| 7 | TWO SIGMA INVESTMENTS, LP | 3.0% | 3,466,786 | $4M |
| 8 | JOHNSON JOHNSON | 2.9% | 3,379,064 | $4M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2.6% | 2,974,683 | $4M |
| 10 | AQR CAPITAL MANAGEMENT LLC | 2.5% | 2,923,910 | $4M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Fate Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Fate Therapeutics Inc 2026 annual meeting?
- Fate Therapeutics Inc (FATE) holds its 2026 annual shareholder meeting on Friday, June 12, 2026.
- What is the record date for the Fate Therapeutics Inc 2026 meeting?
- The record date for the Fate Therapeutics Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Fate Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Fate Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Fate Therapeutics Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Fate Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.